Skip to main content
. 2012 Jan 9;14(1):R10. doi: 10.1186/bcr3091

Table 2.

Characteristics of women with breast cancer

Screen detected cancer Interval cancer
Advanced
N = 570
Non-advanced
N = 1,164
P-
value
Advanced
N = 424
Non-advanced
N = 233
P-
value
Mean age, years (95%CI) 62.0 (61.3 - 62.6) 62.4 (62.0 - 62.8) 0.24 59.5 (58.9 - 60.2) 59.3 (58.4 - 60.2) 0.76
Family history of breast cancer±, No (%) 123 (21.6) 218 (18.7) 0.16 76 (17.9) 43 (18.5) 0.87
Previous breast surgery# 58 (10.0) 130 (11.2) 0.53 72 (15.6) 34 (15.0) 0.43
Use of hormone replacement therapy, No (%) 59 (10.4) 95 (8.2) 0.13 70 (13.1) 20 (6.3) 0.005
Initial screens, No (%) 106 (18.6) 183 (15.7) 0.13 64 (13.5) 32 (11.8) 0.64
Interval between 2 latest screens, No (%) 0.08 - -
< 30 months 527 (92.5) 1,101 (94.6)
≥ 30 months 43 (7.5) 63 (5.4)
Breast density at latest screening mammogram, No (%) 0.45 0.49
≤ 50% 375 (65.8) 787 (67.4) 243 (60.7) 140 (60.1)
> 50% 195 (34.2) 377 (32.4) 181 (39.3) 93 (39.9)
Mammographic abnormality, No (%) < 0.001 0.04
 Density 426 (74.8) 740 (63.6) 133 (64.6) 78 (70.9)
 Microcalcifications 35 (6.1) 280 (24.1) 26 (12.6) 18 (16.4)
 Density with microcalcifications 82 (14.4) 112 (9.6) 16 (7.8) 6 (5.5)
 Architectural distortion 22 (3.9) 24 (2.1) 11 (5.3) 7 (6.4)
 Breast parenchyma asymmetry 4 (0.9) 8 (0.7) 20 (9.7) 1 (0.9)
Breast cancer visible at previous screening mammogram 199 (42.9)* 418 (42.7)¥ 0.95 208 (47.6) 112 (47.4) 0.81
Tumor histology of invasive cancers, No (%) < 0.001 0.09
 Ductal 414 (72.6) 682 (77.7) 304 (71.8) 155 (77.7)
 Lobular 93 (16.3) 85 (9.7) 87 (21.3) 30 (10.9)
 Mixed ductal-lobular 37 (6.5) 41 (4.7) 18 (4.0) 10 (5.9)
 Invasive other 24 (4.2) 68 (7.7) 11 (2.0) 11 (5.5)
 Unknown 2 (0.4) 2 (0.2) 4 (0.9) 0 (0.0)

±At least one first-degree relative (mother, sister, daughter) with a diagnosis of breast cancer before the age of 50 years or at least two second-degree relatives with breast cancer. #Surgery for benign conditions (e.g., excisional biopsy, breast reduction, breast augmentation, mastitis) and malignant conditions (lumpectomy, mastectomy). *464 subsequent screens; ¥979 subsequent screens